Clinical Overview: Hepatitis B Cirrhosis with AKI-on-HRS-on-CKD, Varices, Ascites & Diabetes

1. Problem List (Prioritized)

2. AKI on HRS on CKD — Management

Phenotyping the Renal Dysfunction

• AKI on CKD = acute rise in creatinine ≥ 0.3 mg/dL above CKD baseline
• HRS-AKI = diagnosis of exclusion: no response to fluid challenge (albumin 1 g/kg/day × 2 days), absence of shock, no nephrotoxins, no structural kidney disease on urine microscopy/ultrasound

Key Management Steps (per ACLF guidelines):

1. Identify and treat precipitating factors
   • Screen for SBP (diagnostic paracentesis if ascites present) — PMNS >250 cells/µL
   • Blood/urine/ascitic cultures before starting antibiotics
   • Early empiric antibiotics if infection suspected — every hour delay in antibiotics increases mortality 1.86× from multiorgan failure
   • Avoid nephrotoxic drugs (NSAIDs, aminoglycosides, contrast agents)
2. Fluid challenge
   • IV Albumin 1 g/kg/day × 2 days (max 100 g/day)
   • Withdraw diuretics if hemodynamically unstable
3. HRS-AKI Specific Vasoconstrictors
   • Terlipressin (first-line): 0.5–1 mg IV q4–6h, titrate up to 2 mg q4–6h (preferred if available)
   • Alternative: Noradrenaline + albumin (ICU setting)
   • Midodrine + Octreotide + Albumin (if terlipressin unavailable — less evidence)
4. Hepatitis B Activity Check
   • Ensure patient is on entecavir or tenofovir — active HBV replication worsens hepatic decompensation and contributes to AKI
   • Check HBV DNA, ALT, INR — flares can precipitate ACLF
5. Monitor for ACLF
   • ACLF (acute-on-chronic liver failure) carries very high short-term mortality
   • CLIF-SOFA / NACSELD criteria to grade severity
   • Consider hepatology/transplant team referral if no vasoconstrictor response
6. Renal Replacement Therapy
   • If AKI progresses to severe oliguria/anuria, hyperkalemia, refractory acidosis — consider CRRT as bridge to liver transplantation

3. Esophageal Varices & Ascites

Small Varices (Grade I–II)

• Primary prophylaxis: Non-selective beta-blocker (propranolol or carvedilol)
  • Caution: NSBBs mask hypoglycemia symptoms in diabetics — especially important here
  • Carvedilol 6.25 mg OD may be preferred (also reduces HVPG more effectively)
• Avoid if: refractory ascites, SBP, or hemodynamic instability (MAP <60)
• EGD surveillance: repeat in 2–3 years if no progression; sooner if decompensation

Ascites

• Diuretics: Spironolactone ± furosemide — but hold/withdraw if AKI present
• Low sodium diet: <2 g/day
• Therapeutic paracentesis for tense ascites + IV albumin (8 g per liter removed)
• SBP prophylaxis: norfloxacin or ciprofloxacin (if prior SBP or high-risk ascites protein <1.5 g/dL)

4. Glycemic Management — Key Challenge in This Patient

Current Pattern Analysis

• Significant insulin resistance (common in cirrhosis — hepatic glucose dysregulation)
• Hepatogenous diabetes (peripheral IR + impaired hepatic glucose uptake)
• Inadequate dose for the current carbohydrate load
• Or counterregulatory response if any concurrent hypoglycemic event occurred earlier

Why Diabetes is Especially Dangerous in Cirrhosis (per MASLD/Diabetes guidelines):

• Hypoglycemia risk is markedly elevated due to:
  • Impaired hepatic gluconeogenesis/glycogenolysis
  • Reduced renal insulin clearance (CKD component)
  • Cognitive dysfunction/HE that may mimic or mask hypoglycemia
  • Non-selective beta-blockers (if used for varices) blunt adrenergic hypoglycemia awareness (mask tremor, tachycardia)
• People with T2DM + cirrhosis have much higher risk of severe hypoglycemia and mortality vs. those without cirrhosis

Glycemic Goals in Decompensated Cirrhosis

• Less stringent, individualized targets are recommended
• Target glucose: 140–180 mg/dL (inpatient) — avoid tight control
• HbA1c 7.3% — reasonably acceptable; however, HbA1c may be falsely low in cirrhosis (hemolysis, reduced RBC lifespan) — GRBs / CGM monitoring is more reliable

OHA Considerations in CKD + Cirrhosis

Immediate Recommendations:

1. Review/stop OHA — identify which OHA is being used; metformin and sulfonylureas should be discontinued given AKI + cirrhosis
2. Continue insulin but with caution — reduce dose if renal clearance declining; Actrapid 8U appears insufficient for this pre-meal level; consider adjusting basal insulin if on basal-bolus
3. Frequent GRBs monitoring — q4–6h minimum; watch for nocturnal hypoglycemia
4. Nutritional assessment — cirrhosis patients need adequate caloric intake (35–40 kcal/kg/day); small frequent meals to avoid hypoglycemia between doses

5. Cholelithiasis

• Asymptomatic in context of decompensated cirrhosis — do not operate electively
• Surgical risk is prohibitively high (Child-Pugh C/MELD >15 carries >50% surgical mortality)
• Manage conservatively; only intervene if acute cholecystitis develops (consider percutaneous cholecystostomy over surgery)

6. Summary Management Checklist

• Diagnostic paracentesis — rule out SBP
• Blood/urine cultures, CBC, LFT, INR, creatinine, electrolytes, HBV DNA
• Albumin infusion (1 g/kg/day × 2 days) — fluid challenge
• Hold all diuretics, NSAIDs, nephrotoxins, contrast
• Empiric antibiotics if infection suspected (ceftriaxone 1–2g IV OD)
• Terlipressin if HRS-AKI confirmed and no contraindications
• Ensure on entecavir/tenofovir for HBV
• Stop OHA (especially metformin/sulfonylureas); switch to insulin-only regimen
• Frequent GRBs monitoring; gentle glycemic targets (140–180 mg/dL)
• Propranolol/carvedilol for variceal prophylaxis (hold if hemodynamically unstable)
• Liver transplant evaluation if ACLF criteria met

Sources: Acute-on-Chronic Liver Failure and the Management of Critically Ill Patients with Cirrhosis (p. 16); MASLD in People With Diabetes: The Need for Screening and Early Intervention (p. 18)

Lantus (Glargine) as Basal + Actrapid as Bolus — Preferred

Per Perioperative Diabetes and Hyperglycaemia guidelines (p. 34): Basal-bolus (glargine + rapid-acting) mimics physiological insulin response. Using Actrapid alone as sliding scale is not recommended — it addresses hyperglycemia reactively without providing baseline coverage.

Why Not Actrapid Alone (Sliding Scale)?

• No basal coverage → fasting/overnight hyperglycemia persists
• Sliding scale insulin is reactive, not physiological
• Unpredictable glucose control, higher risk of both hyper- and hypoglycemia

Special Considerations in This Patient

1. AKI on CKD — Reduce Insulin Doses

• Kidneys clear ~30–40% of insulin
• With declining renal function, insulin half-life is prolonged → hypoglycemia risk increases significantly
• Start Lantus at a low dose (0.1–0.15 U/kg/day) and titrate cautiously
• Reduce Actrapid bolus doses accordingly

2. Cirrhosis-Specific

• Unpredictable hepatic glucose metabolism — can swing between insulin resistance (portal hypertension) and hypoglycemia (reduced glycogen stores, poor synthetic function)
• Lantus provides a stable, peakless basal profile — safer than NPH (which has a peak and higher hypoglycemia risk)
• Keep target GRBs 140–180 mg/dL — not tight control

3. Practical Regimen Suggestion

4. Watch for Hypoglycemia

• Beta-blockers (if used for varices) mask hypoglycemic symptoms
• Hepatic encephalopathy can mimic or be confused with hypoglycemia
• Keep glucagon or dextrose readily available